

## Special Issue

# Advancing the Science on Vaccine Hesitancy to Inform Interventions

### Message from the Guest Editors

The uptake of routinely recommended vaccines is suboptimal among some population subgroups in the U.S. A low vaccine uptake can be due to a variety of factors, including barriers to access, lack of trust in institutions, concerns about vaccine safety and efficacy, sociocultural factors, and religious or philosophical beliefs. While evidence-based interventions to promote the uptake of routine child and adult vaccinations exist, stagnating (or declining) rates of vaccine uptake among some groups suggests that new strategies may be needed to prepare the population for advances in vaccine technology and the inevitable next pandemic. This Special Issue will include papers that propose new or adapted conceptual frameworks, measures to assess vaccine hesitancy, qualitative and/or quantitative studies that advance our understanding of what is currently known, and studies evaluating the effectiveness or feasibility of new public health strategies.

### Guest Editors

Dr. Kimberly H. Nguyen

Department of Public Health and Community Medicine, Tufts University Medical School, 136 Harrison Ave, Boston, MA 02111, USA

Prof. Dr. Jennifer Allen

Department of Community Health, Tufts University School of Arts and Sciences, 574 Boston Ave, Medford, MA 02155, USA

### Deadline for manuscript submissions

31 August 2025



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed

---



[mdpi.com/si/193301](https://mdpi.com/si/193301)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).